Epigenomics said this week that current Chief Financial Officer Oliver Schacht will be leaving the company by the end of the first quarter 2011.
Schacht co-founded Epigenomics in 1998 and began his work as CFO in 1999. He has also served as CEO of Epigenomics' US subsidiary in Seattle since January 2006. Prior to joining Epigenomics, Schacht was a consultant with Mercer Management Consulting. He also founded or co-founded several companies, including TherEpi. He holds a Master's Degree and PhD from the University of Cambridge.
Epigenomics said that it has hired Schacht's successor but could not disclose his identity until the first weeks of January due to his current contractual obligations. The company said that the new CFO will join the management team by April 1, 2011.
Carl Hull, president and CEO of Gen-Probe, has been elected as chairman of the California Healthcare Institute for 2011-2012, CHI said this week.
Hull has been a CHI board member since July 2009. He joined Gen-Probe in 2007 as executive vice president and chief operating officer, and was promoted to president in 2008 and CEO in 2009. He previously served as vice president and general manager of the SDS/Arrays business unit of Applied Biosystems, now Life Technologies; and has served as CEO of Applied Imaging.
Thermo Fisher said this week that it has elected Nelson Chai to its board of directors.
Chai is the executive vice president, chief administrative officer, and head of strategy for bank holding company CIT Group. Previously, he served as president, Asia-Pacific, for Bank of America; and executive vice president and CFO of Merrill Lynch. Chai also served in senior positions at Allied Signal, Philip Morris, and Dade-Behring.